DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer Dorigo, O., Fiset, S., MacDonald, L., Bramhecha, Y., Hrytsenko, O., Dirk, B., Rosu, G., Stanford, M. AMER SOC CLINICAL ONCOLOGY. 2020

View details for Web of Science ID 000529994300011